LiteratureThis section has been translated automatically.
- Couture R, Laneuville L, Guimond C et al (1989). Characterization of the peripheral action of neurokinins and neurokinin receptor selective agonists on the rat cardiovascular system. Naunyn-Schmiedeberg's Archives of Pharmacology 340:547-557.
- Garcia-Recio S, Gascón P (2015). Biological and Pharmacological Aspects of the NK1-Receptor. Biomed Res Int. 2015;2015:495704. doi/10.1155/2015/495704
- Karthaus M, Schiel X, Ruhlmann C. H et al (2019). Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. Expert Review of Clinical Pharmacology, 12(7), 661-680. doi/10.1080/17512433.2019.1621162
- Lin KL, Shekar S, Crumbaker M (2025). Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men. N Engl J Med 392:202-203 DOI/10.1056/NEJMc2412361
- Pinkerton JV, Redick DL, Homewood LN, Kaunitz AM. (2023) Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms. J Clin Endocrinol Metab. 18;108(11):e1448-e1449. doi.org/10.1210/clinem/dgad209
- Sass, F, Ma, T, Ekberg JH et al. (2024).NK2R control of energy expenditure and feeding to treat metabolic diseases. Nature 635, 987-1000. doi.org/10.1038/s41586-024-08207-0
- Sun, W., Yang, F., Zhang, H. et al. (2023). Structural insights into neurokinin 3 receptor activation by endogenous and analog peptide agonists. Cell Discov 9, 66. doi.org/10.1038/s41421-023-00564-w
- Thor, D., Prömel, S. Beyond incretins: targeting neurokinin receptors for obesity treatment. Sig Transduct Target Ther 10, 21 (2025). doi.org/10.1038/s41392-024-02100
- Wiedmann C , Paasche A , Nietfeld J et al (2023). Activation of neurokinin-III receptors modulates human atrial TASK-1 currents. J Mol Cell Cardiol 184:26-36. DOI: 10.1016/j.yjmcc.2023.09.010
